Patrick Creechan, Jonathan Salik, Brittany Weber, Taryn Youngstein, Antonio Abbate, Allan Klein, Syed W Haider
{"title":"Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated with IL-1 Blockers for Recurrent Pericarditis.","authors":"Patrick Creechan, Jonathan Salik, Brittany Weber, Taryn Youngstein, Antonio Abbate, Allan Klein, Syed W Haider","doi":"10.1097/FJC.0000000000001837","DOIUrl":"10.1097/FJC.0000000000001837","url":null,"abstract":"<p><strong>Abstract: </strong>As the use of interleukin-1 blockers in recurrent pericarditis has increased, questions regarding infection risk, activity restrictions, and lifestyle considerations have increasingly arisen in clinical practice. We describe expert opinion-based considerations for patient counseling and clinical decision making in this evolving therapeutic context.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"396-399"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148329881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Selective Inhibition of Aldosterone Synthase With Lorundrostat in Uncontrolled Hypertension.","authors":"Alexander E Berezin","doi":"10.1097/FJC.0000000000001868","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001868","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":"88 5","pages":"364-366"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ji'e Yang, Ke Meng, Guohong Wu, Jiayu Liang, Jinyi Lin, Rong Huang, Jian Zhang, Dan Li, Xiangyong Kong, Hao Su, Feng Zhang, Junbo Ge
{"title":"Empagliflozin Reduces Postmyocardial Infarction Inflammation via BDH1/β-Hydroxybutyrate-Mediated NF-κB Modulation in Macrophages and the Heart.","authors":"Ji'e Yang, Ke Meng, Guohong Wu, Jiayu Liang, Jinyi Lin, Rong Huang, Jian Zhang, Dan Li, Xiangyong Kong, Hao Su, Feng Zhang, Junbo Ge","doi":"10.1097/FJC.0000000000001870","DOIUrl":"10.1097/FJC.0000000000001870","url":null,"abstract":"<p><strong>Abstract: </strong>Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor, demonstrates cardioprotective effects in heart failure, and recent trials suggest benefits in acute myocardial infarction (MI). However, the mechanisms underlying its efficacy, particularly its impact on the post-MI inflammatory response, are not fully elucidated. The aim of this study was to investigate whether EMPA modulates post-MI inflammation and to uncover the underlying molecular pathways. C57BL/6J mice undergoing MI were randomized to receive EMPA or saline for 7 days. EMPA treatment significantly improved survival, reduced fibrosis, and enhanced cardiac function. EMPA attenuated the systemic inflammatory response at day 1 post-MI, as evidenced by lower serum levels of IL-1β, IL-6, and CXCL-1. In the infarcted myocardium at day 1 post-MI, EMPA suppressed infiltration of neutrophils and proinflammatory macrophages while increasing anti-inflammatory macrophages. Mechanistically, EMPA upregulated the ketone body metabolic enzyme β-hydroxybutyrate dehydrogenase 1 (BDH1), increasing cardiac β-hydroxybutyrate (β-HB) levels, and subsequently inhibited NF-κB p65 phosphorylation. In immortalized bone marrow-derived macrophages, the anti-inflammatory effect of EMPA was mimicked by β-HB and abolished by Bdh1 knockdown, which was rescued by exogenous β-HB. In conclusion, EMPA attenuates maladaptive inflammation and confers cardioprotection after MI, potentially through a BDH1/β-HB/NF-κB pathway in macrophages. This ketone-mediated immunomodulatory axis, primarily defined in vitro, identifies a novel and potential pharmacological mechanism of sodium-glucose cotransporter 2 inhibition in the context of post-MI inflammation.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"400-411"},"PeriodicalIF":2.5,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmet Ferhat Kaya, Fuat Polat, Görkem Ayhan, Furkan Yetmiş, Emrah Özbek, Veysi Can, Ömer Kümet, Adem Aktan
{"title":"Prognostic Value of Non-Invasive Hepatic Fibrosis Scores Across Acute Coronary Syndrome Subtypes.","authors":"Ahmet Ferhat Kaya, Fuat Polat, Görkem Ayhan, Furkan Yetmiş, Emrah Özbek, Veysi Can, Ömer Kümet, Adem Aktan","doi":"10.1097/FJC.0000000000001896","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001896","url":null,"abstract":"<p><p>Hepatic fibrosis indices have emerged as potential prognostic markers in cardiovascular disease. This observational study included 760 consecutive patients with acute coronary syndrome (STEMI, NSTEMI, and unstable angina pectoris) admitted between March 2020 and May 2024 to evaluate the distribution of APRI, FIB-4, FIB-5, and FIB-6 across ACS subtypes and their predictive value for in-hospital mortality and cardiogenic shock. Fibrosis indices were calculated from admission laboratory values, and multivariate logistic regression and ROC curve analyses were performed. STEMI patients had significantly higher APRI (0.95±1.43 vs. 0.41±0.71 vs. 0.20±0.11), FIB-4 (3.68±4.03 vs. 1.98±2.17 vs. 1.17±0.52), and FIB-5 (5.16±1.08 vs. 4.66±0.84 vs. 4.38±0.43) than NSTEMI and unstable angina patients (all p<0.001). In-hospital mortality and cardiogenic shock occurred in 3.8% and 3.2% of patients, respectively. Cardiogenic shock, reduced left ventricular ejection fraction, and lower serum albumin independently predicted mortality, whereas older age independently predicted cardiogenic shock. None of the hepatic fibrosis indices independently predicted either outcome, and their discriminative performance was limited (AUC 0.526-0.632 for mortality and 0.570-0.662 for cardiogenic shock). These findings indicate that although hepatic fibrosis scores are elevated in STEMI, they primarily reflect the severity of acute myocardial injury rather than providing incremental prognostic value beyond established clinical predictors in patients with acute coronary syndrome.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149286974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Racha Ghoussaini, Aditi Patel, Brady Simpson, Kirollos Gabrah, Romani Wahba, Pramod Mohanty, Sriram Sriperumbuduri, Mohammad Al-Ani, Hamang Patel, Keyur B Shah, Pengyang Li
{"title":"Baroreceptor Dysregulation Mediated via Neurohormonal Mechanisms in Heart Failure and its Influence on Renal Function: Potential Role of Baroreflex Activation Therapy.","authors":"Racha Ghoussaini, Aditi Patel, Brady Simpson, Kirollos Gabrah, Romani Wahba, Pramod Mohanty, Sriram Sriperumbuduri, Mohammad Al-Ani, Hamang Patel, Keyur B Shah, Pengyang Li","doi":"10.1097/FJC.0000000000001895","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001895","url":null,"abstract":"<p><p>Baroreflex activation therapy (BAT), which electrically stimulates carotid sinus baroreceptors to modulate autonomic tone, has emerged as a novel adjunct to guideline-directed medical therapy for resistant hypertension and heart failure. Beyond its established cardiovascular benefits, emerging preclinical and early-phase clinical data suggest that BAT may favorably influence renal function and cardiorenal interactions. By suppressing sympathetic nervous system activity and downregulating the renin-angiotensin-aldosterone system, BAT improves renal hemodynamics and may counteract key mechanisms leading to diuretic resistance. The latter represents a common and clinically significant challenge in patients with advanced heart failure, in whom impaired renal perfusion, neurohormonal activation, and tubular remodeling all contribute to reduced diuretic responsiveness and worsening kidney function. Early evidence indicates that BAT may preserve glomerular filtration rate, reduce proteinuria and improve urinary sodium excretion, suggesting potential renoprotective effects and a therapeutic role in mitigating diuretic resistance. However, these findings remain limited by small sample sizes, short follow-up periods, and heterogenous study populations across diverse clinical settings. This review synthesizes key physiologic mechanisms linking baroreflex signal modulation to renal outcomes and evaluates available clinical data. While BAT offers established cardiovascular benefits in heart failure, its renoprotective and diuretic-sparing potential remains investigational and lacks validation from randomized clinical trials. Dedicated prospective large-scale randomized studies are essential to establish long-term renal efficacy across the cardiorenal disease spectrum.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149267967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the Editor: Comments on \"Differential Binding Affinities and Kinetics of Transthyretin Stabilizers\" by Ji et al.","authors":"Jeffery W Kelly, Evan T Powers","doi":"10.1097/FJC.0000000000001881","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001881","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149267953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
John J Kremer, Sonia Miranda, Axel Vicart, Yuichiro Adachi, Daniel Neddermann, Peter B Senese, Melissa D Zammit, Michael R Gralinski, Gregory S Friedrichs
{"title":"Characterization of a guinea pig model to evaluate cardiovascular toxicity risk for targeted protein degraders - Insights and lessons learned.","authors":"John J Kremer, Sonia Miranda, Axel Vicart, Yuichiro Adachi, Daniel Neddermann, Peter B Senese, Melissa D Zammit, Michael R Gralinski, Gregory S Friedrichs","doi":"10.1097/FJC.0000000000001894","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001894","url":null,"abstract":"<p><p>Targeted protein degradation is an active area of pharmaceutical research and development with the promise to increase the potential number of druggable targets across numerous therapeutic areas. One challenge in their current development has been unexpected cardiovascular findings that have been reported during clinical trials with some degraders, primarily delayed ventricular repolarization manifested as longer corrected QT (QTc) intervals and potential for increased arrhythmic risk. The objective of this study was to investigate whether guinea pigs might be a suitable small animal model to characterize potential cardiovascular effects earlier in degrader development in alignment with 3R principles. The pharmacokinetics and cardiovascular effects were measured in naïve guinea pigs using 4 distinct degraders previously tested in non-human primates. We found exposures were broadly lower in guinea pigs than non-human primates, and dose-limiting toxicity was observed with some degraders after increasing the dose (mg/kg) in guinea pigs to account for the lower exposures. No consistent CV changes were observed across all 4 degraders, which was not translatable to the QTc interval prolongation observed in non-human primates administered the same degraders. Lastly, an anesthetized guinea pig model was investigated to evaluate acute cardiovascular changes at elevated in vivo exposures beyond those achieved in the conscious preparations. However, no consistent changes were observed in QTc intervals. In this context of this preliminary investigation of 4 degraders, the guinea pig model was not a suitable option for evaluating cardiovascular liabilities.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149267945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmed Emara, Mohamed Emara, Ahmed Farid Gadelmawla, Ahmed Mansour, Heba Aboeldahab, Belal Mohamed Hamed, Mohammed AbuBaha, Mahmoud Elbsiony, Mohamed Reyad Mohamed, Michael El Masry
{"title":"Efficacy and Safety of Sotatercept in Pulmonary Arterial Hypertension: A GRADE-Assessed Meta-Analysis of Randomized Trials with Trial Sequential Analysis.","authors":"Ahmed Emara, Mohamed Emara, Ahmed Farid Gadelmawla, Ahmed Mansour, Heba Aboeldahab, Belal Mohamed Hamed, Mohammed AbuBaha, Mahmoud Elbsiony, Mohamed Reyad Mohamed, Michael El Masry","doi":"10.1097/FJC.0000000000001889","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001889","url":null,"abstract":"<p><p>Pulmonary arterial hypertension (PAH) is a progressive disease characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance. Sotatercept, an activin-signaling inhibitor, is a novel therapy targeting this pathology. We conducted a systematic review and meta-analysis to assess its efficacy and safety in PAH. A systematic search of PubMed, Cochrane CENTRAL, Scopus, and Web of Science was conducted, to identify randomized controlled trials (RCTs) evaluating Sotatercept in adults with PAH. Data were pooled using random-effects models to estimate mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). Four RCTs enrolling 921 patients were included. Compared with placebo, Sotatercept significantly improved 6-minute walk distance (MD 30.54 m, 95% CI 4.05-57.04, P=0.02), WHO functional class (RR 1.71, 95% CI 1.37-2.15, P<0.00001), multicomponent improvement (RR 2.77, 95% CI 1.45-5.29, P=0.002), pulmonary vascular resistance (MD -197.01 dyn⋅s⋅cm-5, 95% CI -213.16 - -180.86, P<0.00001), and reduced clinical worsening events (RR 0.28, 95% CI 0.21-0.38, P<0.00001). There were no significant differences in NT-proBNP levels or all-cause mortality. Safety analysis showed lower risks of serious adverse events (AEs), peripheral edema, and right ventricular failure, but higher rates of bleeding, epistaxis, and drug-related AEs. Sotatercept demonstrated meaningful clinical benefits in exercise capacity, hemodynamics, and disease progression among patients with PAH, with a generally acceptable safety profile. These findings support Sotatercept as a promising adjunct to standard therapy, though longer-term trials are needed to confirm durability and survival impact.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149244765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Finerenone: A Non-Steroidal Mineralocorticoid Receptor Antagonist and Its Emerging Role in Cardiovascular-Kidney-Metabolic Syndrome.","authors":"Kyle G Fischer, Craig J Beavers","doi":"10.1097/FJC.0000000000001893","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001893","url":null,"abstract":"<p><p>Cardiovascular-kidney-metabolic (CKM) syndrome represents the interconnected pathophysiology of metabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease, leading to multiorgan dysfunction and elevated adverse outcomes. Overactivation of the mineralocorticoid receptor (MR), via aldosterone-dependent and ligand-independent pathways, drives inflammation, fibrosis, and oxidative stress and facilitates CKM progression. Finerenone is a selective non-steroidal MR antagonist (nsMRA) that exhibits high MR affinity, has balanced cardiac and renal distribution, and minimal off-target steroidal effects, which make it mechanistically different from steroidal MRAs. Large phase 3 trials such as FIDELIO-DKD and FIGARO-DKD in type 2 diabetes with CKD, and FINEARTS-HF in heart failure (HF) with a left ventricular ejection fraction (LVEF) > 40%, demonstrated consistent cardiorenal benefits. The prespecified FINE-HEART pooled analysis showed finerenone reduced all-cause mortality (HR 0.91, 95% CI 0.84-0.99), HF hospitalizations (HR 0.83, 95% CI 0.75-0.92), and the kidney composite outcome (HR 0.80, 95% CI 0.72-0.90), with benefits consistent across CKM components and background therapies including sodium-glucose cotransporter 2 (SGLT2) inhibitors. Recent data from FIND-CKD extend utility to non-diabetic CKD. Various guidelines incorporate finerenone as an additive therapy for patients with persistent albuminuria on maximal renin-angiotensin system inhibition (RASi) + SGLT2i. This review summarizes the MR pathophysiology in CKM syndrome, compares the mechanisms of non-steroidal versus steroidal MRAs, synthesizes clinical trial evidence, safety, and guideline-directed place in therapy, addresses implementation barriers, including cost, and outlines future research directions. Finerenone may fill a critical gap in multimodal CKM management, enabling comprehensive pillar-based therapy to mitigate residual cardiorenal risk.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alex El Darzi, Roy El Darzi, Karim Kanbar, Rabah Iratni, Hisham A Nematalla, Ali H Dakroub, Ali H Eid
{"title":"Targeting Vascular Smooth Muscle Cell Senescence for Cardiovascular Pharmacology: Mechanisms and Therapeutic Perspectives.","authors":"Alex El Darzi, Roy El Darzi, Karim Kanbar, Rabah Iratni, Hisham A Nematalla, Ali H Dakroub, Ali H Eid","doi":"10.1097/FJC.0000000000001891","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001891","url":null,"abstract":"<p><p>Vascular smooth muscle cells (VSMCs) play a central role in maintaining vascular tone, structural integrity, and adaptive remodeling. With aging and chronic cardiometabolic stress, however, VSMCs undergo senescence driven by telomere attrition, oxidative stress, persistent DNA-damage signaling, and dysregulation of the p53/p21 and p16/Rb pathways. This transition is accompanied by acquisition of a senescence-associated secretory phenotype (SASP), which promotes inflammation, extracellular matrix remodeling, calcification and vascular stiffening. Together, these accelerate atherosclerosis, hypertension, aneurysm formation, and related vasculopathies. Growing evidence identifies VSMC senescence as a promising therapeutic entry point for cardiovascular drug discovery. Emerging strategies include senolytics, senomorphics, metabolic modulators, and molecular reprogramming approaches designed to either eliminate senescent cells or attenuate their pathogenic secretome and downstream signaling networks. In this review, the molecular basis of VSMC senescence, its contribution to major vascular disorders, and the therapeutic landscape targeting senescence-associated pathways are discussed, with emphasis on translational opportunities and current barriers to clinical application. A clearer understanding of VSMC senescence may inform the development of mechanism-based interventions to limit vascular dysfunction and age-related cardiovascular disease.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}